S. Weizman

Thyroid function assessment before and after diagnosis of schizophrenia: A community-based study

H. Hermesh, Abraham Weizman, J. Meyerovitch, 2020, Psychiatry Research.

Creatine kinase levels in psychotic patients who use cannabinoids

Amir Fruman, S. Weizman, A. Shelef, 2020, International clinical psychopharmacology.

Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

Abraham Weizman, A. Valevski, A. Krivoy, 2017, EBioMedicine.

Mortality, morbidity and medical resources utilization of patients with schizophrenia: A case-control community-based study

H. Hermesh, B. Stubbs, J. Meyerovitch, 2018, Psychiatry Research.

A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia

R. Stryjer, S. Weizman, A. Shelef, 2021, Journal of clinical psychopharmacology.

Low adherence to antidepressants is associated with increased mortality following stroke: A large nationally representative cohort study

M. Hoshen, R. Balicer, B. Stubbs, 2017, European Neuropsychopharmacology.

Amantadine Augmentation Therapy for Obsessive Compulsive Patients Resistant to SSRIs—An Open-Label Study

B. Spivak, T. Green, R. Stryjer, 2014, Clinical neuropharmacology.

Factors affecting the willingness of mental health staff to get vaccinated against COVID‐19

S. Weizman, A. Shelef, Sagit Dahan, 2022, Journal of evaluation in clinical practice.

Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.

X. Gonda, P. Dome, G. Faludi, 2012, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology.

Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular

R. Stryjer, S. Weizman, A. Shelef, 2021, International Clinical Psychopharmacology.

Inflammation Markers Among Schizophrenia Patients Who Use Cannabis

R. Stryjer, S. Weizman, A. Shelef, 2023, Clinical neuropharmacology.

P.0434 Pre-existing vitamin D supplementation as a protective factor in COVID-19 infection in elderly schizophrenia and dementia inpatients: a case series

S. Dahan, S. Weizman, A. Shelef, 2021, European Neuropsychopharmacology.

Adherence of patients with schizophrenia to hypothyroidism treatment

S. Gur, S. Weizman, Haggai Hermesh, 2023, Cambridge Prisms: Global Mental Health.

Alterations in plasma endocannabinoid concentrations among individuals with major depression treated with electroconvulsive therapy

D. Meiri, R. Stryjer, S. Weizman, 2024, Psychiatry Research.